| Literature DB >> 25344525 |
Kaat Durinck1, Annelynn Wallaert2, Inge Van de Walle3, Wouter Van Loocke2, Pieter-Jan Volders2, Suzanne Vanhauwaert2, Ellen Geerdens4, Yves Benoit2, Nadine Van Roy2, Bruce Poppe2, Jean Soulier5, Jan Cools4, Pieter Mestdagh2, Jo Vandesompele2, Pieter Rondou2, Pieter Van Vlierberghe2, Tom Taghon3, Frank Speleman1.
Abstract
Genetic studies in T-cell acute lymphoblastic leukemia have uncovered a remarkable complexity of oncogenic and loss-of-function mutations. Amongst this plethora of genetic changes, NOTCH1 activating mutations stand out as the most frequently occurring genetic defect, identified in more than 50% of T-cell acute lymphoblastic leukemias, supporting a role as an essential driver for this gene in T-cell acute lymphoblastic leukemia oncogenesis. In this study, we aimed to establish a comprehensive compendium of the long non-coding RNA transcriptome under control of Notch signaling. For this purpose, we measured the transcriptional response of all protein coding genes and long non-coding RNAs upon pharmacological Notch inhibition in the human T-cell acute lymphoblastic leukemia cell line CUTLL1 using RNA-sequencing. Similar Notch dependent profiles were established for normal human CD34(+) thymic T-cell progenitors exposed to Notch signaling activity in vivo. In addition, we generated long non-coding RNA expression profiles (array data) from ex vivo isolated Notch active CD34(+) and Notch inactive CD4(+)CD8(+) thymocytes and from a primary cohort of 15 T-cell acute lymphoblastic leukemia patients with known NOTCH1 mutation status. Integration of these expression datasets with publicly available Notch1 ChIP-sequencing data resulted in the identification of long non-coding RNAs directly regulated by Notch activity in normal and malignant T cells. Given the central role of Notch in T-cell acute lymphoblastic leukemia oncogenesis, these data pave the way for the development of novel therapeutic strategies that target hyperactive Notch signaling in human T-cell acute lymphoblastic leukemia. Copyright© Ferrata Storti Foundation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25344525 PMCID: PMC4258754 DOI: 10.3324/haematol.2014.115683
Source DB: PubMed Journal: Haematologica ISSN: 0390-6078 Impact factor: 9.941